Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Carcinoma, Non-Small-Cell Lung 17Lymphoma, Large-Cell, Anaplastic 6Lung Neoplasms 6Neoplasm Metastasis 5Adenocarcinoma 4Neuroblastoma 2Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Recurrence 1Neurofibromatosis 2 1Lymphoma, Follicular 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Carcinoma, Large Cell 1Advanced Cancer 1ALK-positive NSCLC 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 33pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × Crizotinib × Clear all
NCT02034981 2024-02-28

AcSé

UNICANCER

Phase 2 Completed
246 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01744652 2023-06-07

Dasatinib and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
62 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01579994 2020-12-30

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡